Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. STU /
  3. CJH.STU

CanSino Biologics Inc (CJH STU) stock market data APIs

€2.16 0.02(0.9%) as of July 26, 2024
Price chart is built with Anychart

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc Financial Data Overview

2.14
2.16
-
2.16
2.14
1.803-3.573
868 M
133 M
371 M
0.568
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CJH',
Type: 'Common Stock',
Name: 'CanSino Biologics Inc',
Exchange: 'STU',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'CNE100003F01',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
}

CanSino Biologics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 371 M
  • EBITDA -1 370 357 504
  • Earnings Per Share -0.78
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get CanSino Biologics Inc Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get CanSino Biologics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get CanSino Biologics Inc latest news via APIs

China's CanSino seeks more vaccine contracts after AstraZenca deal

By Brenda Goh and Miyoung Kim SHANGHAI, Aug 31 (Reuters) - China's CanSino Biologics , which recently announced a contract manufacturing deal to support AstraZenca's messenger RNA (mRNA) technology v...

AstraZeneca signs vaccine deal with China’s CanSino

Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’ Continue reading
Do you have any questions?
support@eodhistoricaldata.com